Ixazomib (MLN-2238)

Ixazomib (MLN2238) (commercial name: Ninlaro®) is the first and only FDA-approved oral proteasome inhibitor for the treatment of multiple myeloma. It reversibly inhibits the chymotrypsin-like activity of proteasomes with IC50 of 3.4 nM in cell-free assays, also inhibits the caspase-like and trypsin-like activities of proteasome with IC50 of 31 and 3500 nM, respectively.

Additional Information

Product Name: Ixazomib (MLN-2238)
Also Known As: [(1R)-1-[[(2S,3R)-3-hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]butanoyl]amino]-3-methylbutyl]boronic acid
Catalog No.: F1110
Size: 5 mg
CAS: 1072833-77-2
Formula: C14H19BCl2N2O4
Molecular Weight: 361.03 g/mol
Form: Lyophilized powder
Quality Assurance: >98% by HPLC and NMR
Source: Synthetic
Storage: Eligible for room temperature shipping. Store at -20°C upon receiving; protect from air and ligh
PDF Data Sheet: Download PDF datasheetMSDS
Image(s): N/A
Shipping Method: FedEx
References: N/A

Details

Ixazomib (MLN2238) (commercial name: Ninlaro®) is the first and only FDA-approved oral proteasome inhibitor for the treatment of multiple myeloma. It reversibly inhibits the chymotrypsin-like activity of proteasomes with IC50 of 3.4 nM in cell-free assays, also inhibits the caspase-like and trypsin-like activities of proteasome with IC50 of 31 and 3500 nM, respectively.

Solubility:
> 10 mg/ml in DMSO, < 1mg/mL in water, For in vivo use, >30 mg/mL in 0.5% hydroxyethyl cellulose